IVVD logo

Invivyd, Inc.

IVVD
Healthcare|Biotechnology|US
$0.56
-0.02 (-3.76%)
DCF Value
$10.71
Tangible Book / Share
$0.57
Cash / Share
$0.50
Next Earnings Report
Apr 1, 2027
EPS est. -$0.12 · Revenue est. $17.0M
Financing Filings (last 12 months)
3
Shelf registrations / offering prospectuses — latest Dec 19, 2025 (S-3/A). Possible dilution.

Upcoming Data Readouts (0)

No upcoming completion dates found in active trials.

Awaiting Results (2)

Trials past primary completion date but still active — data readout may be imminent.

Aug 2026
P3
Study of VYD2311 for the Prevention of COVID-19
NCT07298434
May 2025
P1
A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy Participants
NCT06523153

Recent Press Releases

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 3, 2026 · GlobeNewsWire
Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026
Oct 21, 2026 · GlobeNewsWire
Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome
Oct 14, 2026 · GlobeNewsWire
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 5, 2026 · GlobeNewsWire
Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311
Sep 29, 2026 · GlobeNewsWire
Invivyd to Participate in Upcoming September Investor Conferences
Sep 8, 2026 · GlobeNewsWire
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 3, 2026 · GlobeNewsWire
Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY
Sep 1, 2026 · GlobeNewsWire
Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Aug 13, 2026 · GlobeNewsWire

SEC Filings (91)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Sep 29, 20268-KMaterial eventDocumentIndex
Sep 1, 20268-KMaterial eventDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 13, 202610-QQuarterly reportDocumentIndex
Aug 13, 20268-KMaterial eventDocumentIndex
Jul 28, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jul 24, 20268-KMaterial eventDocumentIndex
Jul 6, 20268-KMaterial eventDocumentIndex
May 19, 20268-KMaterial eventDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 14, 2026S-8Employee stock planDocumentIndex
May 14, 202610-QQuarterly reportDocumentIndex
May 14, 20268-KMaterial eventDocumentIndex
Apr 9, 20268-KMaterial eventDocumentIndex
Apr 6, 2026ARSAnnual report to holdersDocumentIndex
Apr 6, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 6, 2026DEF 14AProxy / shareholder voteDocumentIndex
Mar 5, 202610-KAnnual reportDocumentIndex
Mar 5, 20268-KMaterial eventDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 13, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 12, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jan 8, 20268-KMaterial eventDocumentIndex
Dec 29, 2025SC 13D/AActivist / 5%+ stakeDocumentIndex
Dec 23, 2025EFFECTDocumentIndex
Dec 23, 20258-KMaterial eventDocumentIndex
Dec 19, 2025S-3/AShelf registrationDocumentIndex
Nov 25, 2025SC 13GPassive 5%+ stakeDocumentIndex
Nov 24, 20258-KMaterial eventDocumentIndex
Nov 19, 20258-KMaterial eventDocumentIndex
Nov 19, 2025SC 13D/AActivist / 5%+ stakeDocumentIndex
Nov 19, 2025424B5Offering prospectusDocumentIndex
Nov 17, 2025FWPDocumentIndex
Nov 17, 2025424B5Offering prospectusDocumentIndex
Nov 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex